A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Latest Information Update: 26 Jul 2024
At a glance
- Drugs BMS-986340 (Primary) ; Docetaxel (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb
- 31 Jan 2023 According to ClinicalTrials.gov record, protocol has been amended to increase patient number from 185 to 665, treatment arm changed from 4 to 5. Addition of new drug Docetaxel in trial.
- 31 Jan 2023 Planned number of patients changed from 185 to 665.
- 31 Jan 2023 Planned End Date changed from 23 Aug 2025 to 15 Sep 2026.